Investors & Media

March 19, 2026

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

March 13, 2026

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

February 6, 2026

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

January 29, 2026

Immutep Quarterly Activities Report Q2 FY26

December 22, 2025

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

December 16, 2025

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

February 20, 2026

Immutep Corporate Presentation

November 13, 2025

CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)

October 19, 2025

ESMO Congress 2025 – EFTISARC-NEO (Soft Tissue Sarcoma)

October 18, 2025

ESMO Congress 2025 – INSIGHT-003 (First Line Non-Small Cell Lung Cancer)

October 18, 2025

ESMO Congress 2025 – TACTI-004 (First Line Non-Small Cell Lung Cancer)

December 12, 2024

ESMO Immuno-Oncology 2024 – TACTI-003, Cohort B (Metastatic Head and Neck Squamous Cell Carcinoma)